e-learning
resources
ERJ
2015
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Pneumococcal conjugate vaccine for adults: “It's tough to make predictions,…”
Pletz Mathias W., Welte Tobias
Source:
Eur Respir J 2015; 46: 1265-1268
Journal Issue:
November
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Pletz Mathias W., Welte Tobias. Pneumococcal conjugate vaccine for adults: “It's tough to make predictions,…”. Eur Respir J 2015; 46: 1265-1268
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
ERS short guidelines on COVID-19 management
Influenza vaccination: protecting the most vulnerable
Understanding new vaccines for SARS-CoV-2 and their regulation
Related content which might interest you:
Pneumococcal vaccine: when, what, how and to whom
Source: International Congress 2014 – MS06 What's new in pneumococcal vaccination?
Year: 2014
Pneumococcal vaccination: current and future issues
Source: Eur Respir J 2001; 18: 184-195
Year: 2001
Introduction of the 13-valent pneumococcal conjugate vaccine in an isolated pneumococcal vaccine-naïve indigenous population
Source: Eur Respir J 2016; 48: 1492-1496
Year: 2016
Impact of introducing the 10-valent pneumococcal conjugate vaccine on childhood hospitalizations for bacterial pneumonia in Brazil
Source: Annual Congress 2013 –Paediatric respiratory epidemiology: bronchiolitis and asthma
Year: 2013
Pneumococcal vaccination in bronchiectasis- an area for improvement?
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016
Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia
Source: Eur Respir J 2015; 45: 1632-1641
Year: 2015
Clinical presentations and serotypes causing invasive pneumococcal disease in adults vaccinated with the 23-valent polysaccharide pneumococcal vaccine (PPV23) in Spain. The ODIN study (2010-2013)
Source: International Congress 2014 – The epidemiology of respiratory infections and lung cancer
Year: 2014
Pneumococcal vaccination
Source: Eur Respir J 2005; 26: 982-983
Year: 2005
Pneumococcal vaccination practices and recommendations around the world
Source: International Congress 2017 – Global challenges in respiratory medicine
Year: 2017
The remaining challenges of pneumococcal disease in adults
Source: Eur Respir Rev 2012; 21: 57-65
Year: 2012
Assessment of medical undergraduates’ relation to pneumococcal conjugate vaccine use
Source: Virtual Congress 2021 – Medical education in respiratory medicine
Year: 2021
Additive preventive effect of influenza and pneumococcal vaccines in elderly persons
Source: Eur Respir J 2004; 23: 363-368
Year: 2004
Pneumococcal polysaccharide vaccination in COPD patients - some problems with antibody-response
Source: Eur Respir J 2002; 20: Suppl. 38, 472s
Year: 2002
Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases
Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit
Year: 2018
Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine
Source: Eur Respir J 2013; 42: 1595-1603
Year: 2013
Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands
Source: Eur Respir J 2015; 46: 1407-1416
Year: 2015
Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13)
Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept